Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A

NASDAQ:KNSA 4:00:00 PM EDT

36.56

-0.54 (-1.46%)

: $37.00 +0.44 (+1.20%)

Market Cap (Intraday)	2.71B
Current PE	565.61
Forward PE	33.24
2yr Forward PE	22.02

See more stats

Estimates Current Quarter

Revenue	$166.77 Million
Adjusted EPS	$0.33

See more estimates

10-Day MA	$36.15
50-Day MA	$32.10
200-Day MA	$25.14

See more pivots

Kiniksa Pharmaceuticals International Plc. - Ordinary Shares - Class A Stock, NASDAQ:KNSA

23 Old Bond Street, 3rd Floor, London, Greater London W1S 4PZ

United Kingdom

Phone: +44.781.431.9100

Number of Employees: 315

http://www.kiniksa.com

Description

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.